Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
QRxPharma Ltd is an Australia based pharmaceutical company. It is principally engaged in the research and development, and commercialization of biopharmaceutical products. The company’s products include pain management products and abuse prevention products. The pain management products include company’s Dual Opioid platform technology which is a patented fixed-ratio combination of morphine and oxycodone. The abuse prevention products include Stealth Beadlets which are a proprietary, abuse-deterrent technology that can be incorporated into any solid dosage form to confer abuse-deterrent features.
Melbourne, VIC, 3124, Australia